The World Health Organization (WHO) on Monday warned that global shortages last year of popular diabetes medicines that are also used for weight loss, such as Novo Nordisk's Ozempic, had been linked to rising reports of suspected counterfeits. The organization said fake versions of the drugs, which belong to a class called GLP-1 agonists, are most often sold and distributed through unregulated outlets, including social media platforms, and carry serious health risks. Explosive demand for Ozempic and similar drugs that are approved for weight loss, including Eli Lilly's Zepbound and...